Cargando…

Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector

Multiple approaches utilizing viral and DNA vectors have shown promise in the development of an effective vaccine against HIV. In this study, an alternative replication-defective flavivirus vector, RepliVax (RV), was evaluated for the delivery of HIV-1 immunogens. Recombinant RV-HIV viruses were eng...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giel-Moloney, M., Esteban, M., Oakes, B. H., Vaine, M., Asbach, B., Wagner, R., Mize, G. J., Spies, A. G., McElrath, J., Perreau, M., Roger, T., Ives, A., Calandra, T., Weiss, D., Perdiguero, B., Kibler, K. V., Jacobs, B., Ding, S., Tomaras, G. D., Montefiori, D. C., Ferrari, G., Yates, N. L., Roederer, M., Kao, S. F., Foulds, K. E., Mayer, B. T., Bennett, C., Gottardo, R., Parrington, M., Tartaglia, J., Phogat, S., Pantaleo, G., Kleanthous, H., Pugachev, K. V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934588/ https://www.ncbi.nlm.nih.gov/pubmed/31882800 http://dx.doi.org/10.1038/s41598-019-56550-4

Ejemplares similares

Application of replication-defective West Nile virus vector to non-flavivirus vaccine targets
por: Giel-Moloney, Maryann, et al.
Publicado: (2017)

Profiles of Human Serum Antibody Responses Elicited by Three Leading HIV Vaccines Focusing on the Induction of Env-Specific Antibodies
por: Vaine, Michael, et al.
Publicado: (2010)

Correction for Kibler et al., “Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC”
por: Kibler, Karen V., et al.
Publicado: (2019)

OA021-01. Construction and characterization of replication competent attenuated NYVAC-based vectors as potential HIV vaccines
por: Jacobs, B, et al.
Publicado: (2009)

Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting
por: Spearman, P, et al.
Publicado: (2012)

Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
por: Goepfert, P, et al.
Publicado: (2012)

A Novel HIV Vaccine Adjuvanted by IC31 Induces Robust and Persistent Humoral and Cellular Immunity
por: Pattacini, Laura, et al.
Publicado: (2012)

P17-23. Enhanced expression of HIV antigens and improved antigen presentation after infection with replication competent attenuated vaccinia virus in vitro
por: Quakkelaar, E, et al.
Publicado: (2009)

Prenatal exposure to consumer product chemical mixtures and size for gestational age at delivery
por: Bommarito, P. A., et al.
Publicado: (2021)

$h \to \mu^{+}\mu^{-}$ via Gluon Fusion at the LHC
por: Han, T, et al.
Publicado: (2002)

A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design
por: Chen, Y, et al.
Publicado: (2012)

Early and Long-Term HIV-1 Immunogenicity Induced in Macaques by the Combined Administration of DNA, NYVAC and Env Protein-Based Vaccine Candidates: The AUP512 Study
por: Perdiguero, Beatriz, et al.
Publicado: (2022)

OA021-04. HIV-1 gp41 envelope MPER mutation altered epitope conformation in lipid and increased sensitivity to 2F5 and 4E10 neutralizing antibodies
por: Shen, X, et al.
Publicado: (2009)

Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial
por: Pantaleo, Giuseppe, et al.
Publicado: (2019)

rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1
por: Montefiori, DC, et al.
Publicado: (2012)

Safety and Immunogenicity of an HIV Adenoviral Vector Boost after DNA Plasmid Vaccine Prime by Route of Administration: A Randomized Clinical Trial
por: Koblin, Beryl A., et al.
Publicado: (2011)

First-Trimester Urine Concentrations of Phthalate Metabolites and Phenols and Placenta miRNA Expression in a Cohort of U.S. Women
por: LaRocca, Jessica, et al.
Publicado: (2015)

RV144-like trial in macaques using ALVAC-SIV & gp120 induces innate immunity and increases the frequency of NK22 & NKG2A+ cells in mucosal tissues
por: Liyanage, NP, et al.
Publicado: (2012)

In Men at Risk of HIV Infection, IgM, IgG1, IgG3 and IgA Reach the Human Foreskin Epidermis
por: Lemos, Maria P., et al.
Publicado: (2015)

Fetal growth in environmental epidemiology: mechanisms, limitations, and a review of associations with biomarkers of non-persistent chemical exposures during pregnancy
por: Kamai, Elizabeth M., et al.
Publicado: (2019)

Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054)
por: Peiperl, Laurence, et al.
Publicado: (2010)

P13-07 LB. A human blocking antibody to CCR5 partially protects against lentiviral infection in non-human primates
por: Pegu, A, et al.
Publicado: (2009)

Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults
por: Buchbinder, Susan P., et al.
Publicado: (2017)

Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques
por: Zurawski, Gerard, et al.
Publicado: (2016)

A bolt from the blue; A case report of an unusual asthma exacerbation
por: Moloney, C., et al.
Publicado: (2019)

HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life
por: Yates, N L, et al.
Publicado: (2013)

Emergent Electroweak Gravity
por: McElrath, Bob
Publicado: (2008)

Laboratory tests for the cosmic neutrino background using beta-decaying nuclei
por: McElrath, Bob
Publicado: (2009)

On The Origin of Neutrino Mass and Mixing in the Standard Model
por: McElrath, Bob
Publicado: (2009)

HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens
por: Shen, Xiaoying, et al.
Publicado: (2020)

Prevalence of High-Intensity Drinking from Adolescence through Young Adulthood: National Data from 2016-2017
por: Patrick, Megan E, et al.
Publicado: (2019)

Black–White Disparities in Criminal Justice Referrals to Drug Treatment: Addressing Treatment Need or Expanding the Diagnostic Net?
por: McElrath, Karen, et al.
Publicado: (2016)

The national prevalence of adolescent nicotine use in 2017: Estimates taking into account student reports of substances vaped()
por: Miech, Richard, et al.
Publicado: (2019)

Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection
por: Astronomo, Rena D., et al.
Publicado: (2016)

Evaluation of symmetry behavior of surgically assisted rapid maxillary expansion with simulation-driven targeted bone weakening
por: Chhatwani, S., et al.
Publicado: (2021)

Longitudinal profiles of plasma eicosanoids during pregnancy and size for gestational age at delivery: A nested case-control study
por: Welch, Barrett M., et al.
Publicado: (2020)

P19-48. Induction of Ad5 neutralizing antibodies in placebo recipients during the Step Trial is not associated with risk of HIV infection
por: Spies, G, et al.
Publicado: (2009)

Observation of Kuznetsov-Ma soliton dynamics in optical fibre
por: Kibler, B., et al.
Publicado: (2012)

P14-11. Educating community medical providers about HIV vaccine induced seropositivity
por: Mark, KE, et al.
Publicado: (2009)

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines
por: Laher, Fatima, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_clf17jqnb64r2jl596i90hkjur